Maja M. Janas De Angelis, PhD, Alnylam Pharmaceuticals, Inc.

Advancing the Safety and Reach of RNAi Therapeutics

Biography:

Maja Janas De Angelis, PhD, DABT is currently an Associate Director, Investigative Toxicology, at Alnylam Pharmaceuticals. She earned her Bachelor of Arts in Chemistry and Biochemistry from the University of Colorado in 2007, and her PhD in Biological and Biomedical Sciences from Harvard University in 2012, working with Dr. Carl D. Novina on novel regulators of microRNA biogenesis and function. After completing her PhD, Dr. Janas De Angelis accepted a position as Presidential Postdoctoral Fellow in the RNAi Therapeutics group at Novartis Institutes for BioMedical Research, working on mechanisms of selective microRNA export via exosomes and novel roles of double-stranded RNA binding proteins in microRNA and siRNA pathways. In 2014, Dr. Janas De Angelis joined the Investigative Toxicology group at Alnylam Pharmaceuticals, where she is championing a variety of investigative, molecular mechanism-based research efforts related to preclinical safety evaluation and CNS targeting of RNAi therapeutics.